Cargando…

Baseline tumour measurements predict survival in advanced non-small cell lung cancer

BACKGROUND: The association between tumour measurements and survival has been studied extensively in early-stage and locally advanced non-small cell lung cancer (NSCLC). We analysed these factors in patients with advanced NSCLC. METHODS: Data were derived from the E4599 trial of paclitaxel-carboplat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gerber, D E, Dahlberg, S E, Sandler, A B, Ahn, D H, Schiller, J H, Brahmer, J R, Johnson, D H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776984/ https://www.ncbi.nlm.nih.gov/pubmed/23942074 http://dx.doi.org/10.1038/bjc.2013.472

Ejemplares similares

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours
por: Bowles, D W, et al.
Publicado: (2013)

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
por: Novello, S, et al.
Publicado: (2009)

Lung cancer survival in England: trends in non-small-cell lung cancer survival over the duration of the National Lung Cancer Audit
por: Khakwani, A, et al.
Publicado: (2013)

A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer
por: Chen, H, et al.
Publicado: (2014)

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
por: Kozloff, M F, et al.
Publicado: (2012)

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours
por: Lankheet, N A G, et al.
Publicado: (2014)

Circadian function in patients with advanced non-small-cell lung cancer
por: Levin, R D, et al.
Publicado: (2005)

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib
por: Satouchi, M, et al.
Publicado: (2007)

Survival in Malignant Peripheral Nerve Sheath Tumours: A Comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours
por: Porter, D. E., et al.
Publicado: (2009)

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients
por: Koivunen, J P, et al.
Publicado: (2008)

Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma
por: Cella, D, et al.
Publicado: (2012)

Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: the relationship to patient survival, tumour biology and local lymphocytic response to tumour
por: Pine, J K, et al.
Publicado: (2015)

The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer
por: van Wyk, Hester C, et al.
Publicado: (2016)

Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer
por: Gagnon, B, et al.
Publicado: (2010)

Baseline psychosocial predictors of survival in localised breast cancer
por: Lehto, U-S, et al.
Publicado: (2006)

Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel
por: Langer, C J, et al.
Publicado: (2015)

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours
por: Kerklaan, B Milojkovic, et al.
Publicado: (2015)

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
por: Boss, D S, et al.
Publicado: (2012)

Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study
por: Seamon, Leigh G, et al.
Publicado: (2018)

Incidence and Survival of Patients with Small Intestinal Neuroendocrine Tumours in a Danish NET Center
por: Hoej, Lise Brehm, et al.
Publicado: (2012)

Small Intestinal Tumours
por: Kopáčová, Marcela, et al.
Publicado: (2013)

Long Term Survival Analysis of Hepatectomy for Neuroendocrine Tumour Liver Metastases
por: Cheung, Tan To, et al.
Publicado: (2014)

The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma – a retrospective analysis of 392 cases
por: Guggenheim, M, et al.
Publicado: (2008)

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer
por: Coleman, R E, et al.
Publicado: (2010)

Montreal prognostic score: estimating survival of patients with non-small cell lung cancer using clinical biomarkers
por: Gagnon, B, et al.
Publicado: (2013)

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
por: Dean, E, et al.
Publicado: (2012)

Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2005)

Relative survival of patients with non-malignant central nervous system tumours: a descriptive study by the Austrian Brain Tumour Registry
por: Woehrer, A, et al.
Publicado: (2014)

Quality of life after prostate cancer treatments in patients comparable at baseline
por: van Tol-Geerdink, J J, et al.
Publicado: (2013)

Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer
por: von Plessen, C, et al.
Publicado: (2006)

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma
por: Zurita, A J, et al.
Publicado: (2017)

Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer
por: Hong, Y S, et al.
Publicado: (2006)

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
por: Yang, J J, et al.
Publicado: (2017)

Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10–17)
por: Choi, Y J, et al.
Publicado: (2015)

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours
por: Yap, T A, et al.
Publicado: (2012)

Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy
por: Grossi, F, et al.
Publicado: (2017)

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study
por: Isakoff, S J, et al.
Publicado: (2014)

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
por: Blagden, S P, et al.
Publicado: (2008)

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
por: Ahn, H K, et al.
Publicado: (2013)

Phase I trial outcomes in older patients with advanced solid tumours
por: Khan, K H, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_c3qsucug3goh8v65r3juaeltje